Moderna Share Price (NASDAQ: MRNA)

$28.28

▲

0.26

(0.93%)

Live

Last updated on August 18, 2025 at 11:40 PM IST

$₹

Check the interactive Moderna Stock chart to analyse performance

Moderna stock performance

as on August 18, 2025 at 11:40 PM IST

Today's Low:$27.98
Today's High:$28.51
$28.28
1.06%
Downside
Day's Volatility :1.86%
Upside
0.81%
52 Weeks Low:$23.15
52 Weeks High:$91.99
$28.28
18.14%
Downside
52 Weeks Volatility :74.83%
Upside
69.26%

Moderna Stock Returns

Period	Moderna, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	6.18%	2.3%	0.0%
6 Months	-21.62%	-5.8%	0.0%
1 Year	-68.85%	-10.9%	0.0%
3 Years	-80.82%	2.8%	-11.6%

Moderna, Inc. Key Stats

Check Moderna key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$28.02
Open	$26.91
Today's High	$28.51
Today's Low	$27.98
Market Capitalization	$10.9B
Today's Volume	$9.4M
52 Week High	$91.99
52 Week Low	$23.15
Revenue TTM	$3.1B
EBITDA	$-3.1B
Earnings Per Share (EPS)	$-7.51
Profit Margin	-94.31%
Quarterly Earnings Growth YOY	-0.85%
Return On Equity TTM	-27.5%

Stock Returns calculator for Moderna Stock including INR - Dollar returns

The Moderna stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Moderna investment value today

Current value as on today

₹35,510

Returns

₹64,490

(-64.49%)

Returns from Moderna Stock

₹68,564 (-68.56%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Moderna Stock

-9.96%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Investment in Moderna Shares from India has dropped by -9.96% over the past 30 days, indicating reduced transactional activity.

-12%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Moderna Stock from India on INDmoney has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Moderna Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	2751	1.05	0.02%

Global Institutional Holdings in Moderna, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
10.72%
BlackRock Inc
6.99%
Baillie Gifford & Co Limited.
5.68%
FMR Inc
5.43%
State Street Corp
4.57%
D. E. Shaw & Co LP
1.92%

Analyst Recommendation on Moderna Stock

Rating

Trend

Buy

54%Buy

35%Hold

9%Sell

Based on 31 Wall street analysts offering stock ratings for Moderna(by analysts ranked 0 to 5 stars)

Moderna Share Price Target

What analysts predicted

Upside of 61.24%

Target:

$45.60

Current:

$28.28

Moderna share price target is $45.60, a slight Upside of 61.24% compared to current price of $28.28 as per analysts' prediction.

Moderna Stock Insights

Price Movement
In the last 7 days, MRNA stock has moved up by 10.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 107.0M → 142.0M (in $), with an average increase of 24.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -1.12B → -825.0M (in $), with an average increase of 16.5% per quarter
MRNA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 135.1%
MRNA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 182.2%
Price to Sales
ForMRNA every $1 of sales, investors are willing to pay $3.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Moderna, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$48.0M	↓ 60.79%
Net Income	$-514.0M	↑ 33.6%
Net Profit Margin	-1.1K%	↓ 756.03%

	FY20	Y/Y Change
Revenue	$274.5M	↑ 471.43%
Net Income	$-747.1M	↑ 45.34%
Net Profit Margin	-272.16%	↑ 797.91%

	FY21	Y/Y Change
Revenue	$17.7B	↑ 6361.44%
Net Income	$12.2B	↓ 1733.33%
Net Profit Margin	68.8%	↑ 340.96%

	FY22	Y/Y Change
Revenue	$18.9B	↑ 6.42%
Net Income	$8.4B	↓ 31.47%
Net Profit Margin	44.3%	↓ 24.5%

	FY23	Y/Y Change
Revenue	$6.8B	↓ 63.72%
Net Income	$-4.7B	↓ 156.37%
Net Profit Margin	-68.84%	↓ 113.14%

	FY24	Y/Y Change
Revenue	$3.2B	↓ 53.29%
Net Income	$-3.6B	↓ 24.46%
Net Profit Margin	-111.32%	↓ 42.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$167.0M	↓ 94.06%
Net Income	$-1.2B	↓ 641.47%
Net Profit Margin	-703.59%	↓ 711.3%

	Q2 FY24	Q/Q Change
Revenue	$221.0M	↑ 32.34%
Net Income	$-1.3B	↑ 8.85%
Net Profit Margin	-578.73%	↑ 124.86%

	Q3 FY24	Q/Q Change
Revenue	$1.9B	↑ 739.37%
Net Income	$13.0M	↓ 101.02%
Net Profit Margin	0.7%	↑ 579.43%

	Q4 FY24	Q/Q Change
Revenue	$956.0M	↓ 48.46%
Net Income	$-1.1B	↓ 8715.38%
Net Profit Margin	-117.15%	↓ 117.85%

	Q1 FY25	Q/Q Change
Revenue	$107.0M	↓ 88.81%
Net Income	$-971.0M	↓ 13.3%
Net Profit Margin	-907.48%	↓ 790.33%

	Q2 FY25	Q/Q Change
Revenue	$142.0M	↑ 32.71%
Net Income	$-825.0M	↓ 15.04%
Net Profit Margin	-580.99%	↑ 326.49%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$48.0M	↓ 114.49%

	FY20	Y/Y Change
Profit	$266.6M	↑ 454.91%

	FY21	Y/Y Change
Profit	$15.1B	↑ 5571.96%

	FY22	Y/Y Change
Profit	$13.5B	↓ 10.98%

	FY23	Y/Y Change
Profit	$2.2B	↓ 83.99%

	FY24	Y/Y Change
Profit	$1.7B	↓ 19.49%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$71.0M	↓ 96.23%

	Q2 FY24	Q/Q Change
Profit	$106.0M	↑ 49.3%

	Q3 FY24	Q/Q Change
Profit	$1.3B	↑ 1165.09%

	Q4 FY24	Q/Q Change
Profit	$217.0M	↓ 83.82%

	Q1 FY25	Q/Q Change
Profit	$17.0M	↓ 92.17%

	Q2 FY25	Q/Q Change
Profit	$23.0M	↑ 35.29%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-459.0M	↑ 38.72%
Investing Cash Flow	$-14.9M	↓ 95.99%
Financing Cash Flow	$51.1M	↓ 95.83%

	FY20	Y/Y Change
Operating Cash Flow	$2.0B	↓ 541.64%
Investing Cash Flow	$-1.7B	↑ 11087.21%
Financing Cash Flow	$2.0B	↑ 3877.22%

	FY21	Y/Y Change
Operating Cash Flow	$13.6B	↑ 571.94%
Investing Cash Flow	$-8.5B	↑ 409.77%
Financing Cash Flow	$-873.0M	↓ 142.94%

	FY22	Y/Y Change
Operating Cash Flow	$5.0B	↓ 63.43%
Investing Cash Flow	$-5.2B	↓ 39.27%
Financing Cash Flow	$-3.4B	↑ 294.96%

	FY23	Y/Y Change
Operating Cash Flow	$-3.1B	↓ 162.6%
Investing Cash Flow	$4.2B	↓ 181.26%
Financing Cash Flow	$-1.4B	↓ 60.06%

	FY24	Y/Y Change
Operating Cash Flow	$-3.0B	↓ 3.66%
Investing Cash Flow	$1.9B	↓ 53.66%
Financing Cash Flow	$56.0M	↓ 104.07%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-989.0M	↓ 259.0%
Investing Cash Flow	$118.0M	↓ 121.93%
Financing Cash Flow	$14.0M	↓ 112.84%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.3B	↑ 28.82%
Investing Cash Flow	$1.6B	↑ 1297.46%
Financing Cash Flow	$34.0M	↑ 142.86%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-1.6B	↑ 22.92%
Investing Cash Flow	$721.0M	↓ 56.28%
Financing Cash Flow	$11.0M	↓ 67.65%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$825.0M	↓ 152.68%
Investing Cash Flow	$-539.0M	↓ 174.76%
Financing Cash Flow	$-3.0M	↓ 127.27%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-1.0B	↓ 225.7%
Investing Cash Flow	$730.0M	↓ 235.44%
Financing Cash Flow	$4.0M	↓ 233.33%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-919.0M	↓ 11.38%
Investing Cash Flow	$564.0M	↓ 22.74%
Financing Cash Flow	$9.0M	↑ 125.0%

Moderna Technicals Summary

Sell

Neutral

Buy

Moderna is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Moderna, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Moderna, Inc.	-9.53%	-21.62%	-68.85%	-80.82%	-58.79%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Moderna, Inc.	24.73	NA	0.0	-9.75	-0.28	-0.15	NA	24.16
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Moderna, Inc.	Buy	$10.9B	-58.79%	24.73	-94.31%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Moderna, Inc.

Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the Moderna COVID-19 vaccine. The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna, Inc. has a market cap of $29.83 Billion. It has a P.E ratio of -5.08. The shares of Moderna, Inc. are trading at $28.02. .

Organization	Moderna
Employees	5800
CEO	Mr. Stéphane Bancel
Industry	Health Technology

Key Management of Moderna, Inc.

Name	Title
Mr. Stéphane Bancel	CEO & Director
Dr. Stephen Hoge M.D.	President
Mr. James M. Mock	Chief Financial Officer
Ms. Shannon Thyme Klinger J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jerh Collins Ph.D.	Chief Technical Operations & Quality Officer
Ms. Lavina Talukdar CFA	Senior VP & Head of Investor Relations
Ms. Tracey Franklin	Chief People & Digital Technology Officer
Dr. Melanie Ivarsson M.B.A., O.B.E., Ph.D.	Chief Development Officer
Mr. Dave Johnson	Chief Data & AI Officer
Dr. Charbel Haber M.P.H., Ph.D.	Senior VP & Head of Global Regulatory Science

Important FAQs about investing in MRNA Stock from India :

What is Moderna share price today?

Moderna share price today is $28.28 as on August 18, 2025 at 11:40 PM IST. Moderna share today touched a day high of $28.51 and a low of $27.98.

What is the 52 week high and 52 week low for Moderna share?

Moderna share touched a 52 week high of $91.99 and a 52 week low of $23.15. Moderna stock price today, August 18, 2025 at 11:40 PM IST is trending at $28.28, lower by 69.26% versus the 52 week high.

How to invest in Moderna Stock (MRNA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Moderna on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Moderna Shares that will get you 0.0530 shares as per Moderna share price of $28.28 per share as on August 18, 2025 at 11:40 PM IST.

What is the minimum amount required to buy Moderna Stock (MRNA) from India?

Indian investors can start investing in Moderna (MRNA) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Moderna stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Moderna share’s latest price of $28.28 as on August 18, 2025 at 11:40 PM IST, you will get 0.3536 shares of Moderna. Learn more about fractional shares .

What are the returns that Moderna has given to Indian investors in the last 5 years?

Moderna stock has given -58.79% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?